Investigator, Principal |
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia |
|
|
| Completed | N/A | 450 | RoW | | Daiichi Sankyo Co., Ltd. | Gastric Cancer | 11/23 | 11/23 | | |
NCT03866707: Epigenetic and Metabolomic Changes in Childhood Cancer Survivors |
|
|
| Terminated | N/A | 7 | US | One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis | Wake Forest University Health Sciences | Childhood Cancer | 05/20 | 05/20 | | |
| Completed | N/A | 11 | US | Psychosocial intervention | Medical University of South Carolina | Aphasia, Stroke | 12/23 | 12/23 | | |
NCT06210776: A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) |
|
|
| Recruiting | N/A | 800 | RoW | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer | 03/28 | 03/28 | | |
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA |
|
|
| Active, not recruiting | N/A | 46 | US | POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care) | University of Arkansas | Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis | 04/23 | 12/24 | | |
NCT06204900: A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery. |
|
|
| Not yet recruiting | N/A | 30 | US | Nerve Cuff and Retractor System | Retropsoas Technologies, LLC | Undergoing a Single-level or Two-level TLIF Surgery | 06/24 | 08/24 | | |
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator |
|
|
| Recruiting | N/A | 60 | US | Wearable Cardioverter Defibrillator, AUDICOR AM | Zoll Medical Corporation | Heart Failure | 03/24 | 05/24 | | |
| Recruiting | N/A | 60 | US | BHmApp | William Beaumont Hospitals, University of Pennsylvania | Urinary Incontinence | 08/24 | 08/24 | | |
| Recruiting | N/A | 200 | Europe | | Chelsea and Westminster NHS Foundation Trust, ViiV Healthcare | HIV Infections, Gender Identity, Human Immunodeficiency Virus | 04/24 | 10/25 | | |
| Active, not recruiting | N/A | 70 | US | PQ Bypass System | Endologix | Peripheral Artery Diseases | 06/24 | 06/24 | | |
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women |
|
|
| Active, not recruiting | N/A | 31 | US | MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE | University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC) | Diastolic Dysfunction | 07/25 | 08/25 | | |
NCT06361797: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes |
|
|
| Not yet recruiting | N/A | 150 | US | Rotator cuff repair augmented with whole bone marrow, Whole bone marrow, Bone marrow aspirate, Rotator cuff repair augmented with concentrated bone marrow, Bone marrow-derived mesenchymal stem cells, Bone marrow concentrate | Johns Hopkins University, ON Foundation | Rotator Cuff Tears | 07/26 | 12/27 | | |
NCT06340503: Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors |
|
|
| Recruiting | N/A | 20 | US | Research-grade accelerometer, National Comprehensive Cancer Network (NCCN) Education Materials, Garmin Vivofit activity tracker, Exercise Consultation Calls, Interview, Physical Activity Index Assessment (Intervention Arm), Physical Activity Index Assessment (Control Arm), Health Surveys | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Breast Cancer, Colon Cancer | 07/25 | 08/25 | | |
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults |
|
|
| Recruiting | N/A | 576 | US | Home Based Care Team, Telephone Based Care Team | UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut | Dementia, Depression, Delirium | 07/24 | 07/24 | | |
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings |
|
|
| Recruiting | N/A | 780 | US | Financial Navigation | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Neoplasms, Carcinoma | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 80 | US | Gaming in a virtual environment | Yale University, National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases | 07/25 | 07/25 | | |
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment |
|
|
| Completed | N/A | 136 | Canada | Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine. | Prollenium Medical Technologies Inc. | Volume Deficit in the Mid-face | 08/23 | 08/23 | | |
| Not yet recruiting | N/A | 16 | US | KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Radiation Dermatitis | 08/26 | 08/26 | | |
| Active, not recruiting | N/A | 5000 | RoW | Edoxaban | Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd. | Non-valvular Atrial Fibrillation | 10/24 | 10/24 | | |
ROCK-RT, NCT05169177: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy |
|
|
| Recruiting | N/A | 50 | RoW | | University of Sydney, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia | Liver Neoplasm | 10/24 | 10/26 | | |
NCT01336790: International Lymphatic Disease and Lymphedema Registry |
|
|
| Recruiting | N/A | 5000 | US | | Stanford University, Lymphatic Education & Research Network | Lymphedema | 12/24 | 12/25 | | |
NCT05531357: Physiologic Mechanisms Underlying Ovarian Follicular Waves During the Menstrual Cycle |
|
|
| Completed | N/A | 50 | Canada | Transvaginal ultrasound scans, Finger-prick blood sampling for dried blood spots, Urine sampling, Venipunctures | University of Saskatchewan, Ansh Labs | Reproductive Issues | 03/24 | 03/24 | | |
| Recruiting | N/A | 200 | US | Education and counseling, Education | Georgetown University | Breast Cancer | 12/24 | 12/25 | | |
NCT05689190: Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD) |
|
|
| Recruiting | N/A | 30 | Europe | | Philips Clinical & Medical Affairs Global, Leiden University Medical Center | Lower Extremity Arterial Disease | 12/24 | 12/24 | | |
NCT05862467: A Pilot Participatory Program Evaluation of a Virtual Trauma Support Program for Autistic Adults |
|
|
| Recruiting | N/A | 30 | US | Written Exposure Therapy (WET) via telehealth | University of Wyoming | Autism, Trauma, Posttraumatic Stress Disorder, Posttraumatic Stress Symptom | 05/25 | 05/25 | | |
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
|
|
| Recruiting | N/A | 30 | US | TURALIO™ | Daiichi Sankyo, Inc. | Hepatotoxicity, Tenosynovial Giant Cell Tumor | 06/25 | 03/36 | | |
| Recruiting | N/A | 198 | US | Dietary Intervention Classes | University of South Carolina | Diabetes Mellitus, Type 2, Obesity | 12/25 | 03/26 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
NCT06054412: An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers |
|
|
| Recruiting | N/A | 20 | US | Neuroptimal (Zengar, Inc.) Neurofeedback | Wayne State University | Well-Being, Psychological, Dissociation, Maternal Care Patterns, Maternal Behavior, Maternal Distress, Mood Disturbance, Emotional Regulation, Post Traumatic Stress Disorder | 09/25 | 03/26 | | |
| Active, not recruiting | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 12/25 | 08/26 | | |
SILVERCARE_AF, NCT05804747: A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation |
|
|
| Recruiting | N/A | 1100 | RoW | Edoxaban | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Atrial Fibrillation | 12/25 | 12/25 | | |
LEARN, NCT05184790: Learning Environment for Artificial Intelligence in Radiotherapy New Technology |
|
|
| Not yet recruiting | N/A | 300 | RoW | | University of Sydney, Princess Alexandra Hospital, Brisbane, Australia, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia | Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer, Spinal Neoplasm | 01/26 | 01/26 | | |
NCT05022862: Economic Incentives and vDOT for Latent Tuberculosis Infection |
|
|
| Recruiting | N/A | 399 | US | Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Latent Tuberculosis | 04/26 | 10/26 | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
NCT05636397: Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC |
|
|
| Recruiting | N/A | 60 | Canada | L-Citrulline | The Hospital for Sick Children | BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension, NEC | 12/27 | 03/28 | | |
NCT05181163: Biofilm Formation and Antibiotic Sensitivity Patterns |
|
|
| Not yet recruiting | N/A | 100 | NA | swab | Sohag University | Orthopedic Surgery | 07/22 | 01/23 | | |
Marth, Christian |
| Recruiting | 3 | 540 | Europe | Letrozole 2.5mg, Femara, Placebo | Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma | 10/25 | 10/30 | | |
NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer |
|
|
| Recruiting | 2/3 | 268 | Europe, Canada, US, RoW | Navtemadlin, KRT-232, Navtemadlin Placebo | Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation | Endometrial Cancer | 08/25 | 07/27 | | |
SHAPE, NCT01658930: Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer |
|
|
| Active, not recruiting | N/A | 700 | Europe, Canada, RoW | Radical Hysterectomy + pelvic lymph node dissection, Simple hysterectomy + pelvic lymph node dissection | Canadian Cancer Trials Group, Gynecologic Cancer Intergroup (GCIG), Canadian Institutes of Health Research (CIHR), Korean Gynecologic Oncology Group, Dutch Gynecologic Oncology Group, Cancer Trials Ireland, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Belgium Gynecologic Oncology Group, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Institute of Cancer Research, United Kingdom, Shanghai Cancer Centre Deptartment of Gynecologic Oncology Fudan University, Hertzen Moscow Scientific Research Institute of Oncology, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany, Institut Claudius Regaud - Institute Universitaire du Cancer de Toulouse - Oncopole | Cervical Cancer | 03/23 | 12/24 | | |
NCT04369352: Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria |
|
|
| Recruiting | N/A | 150 | Europe | | Medical University Innsbruck | Recurrent Ovarian Carcinoma | 12/24 | 08/25 | | |
Seppi, Klaus |
| Recruiting | 2 | 138 | Europe, Japan, US | TAK-341, MEDI1341, Placebo | Takeda, AstraZeneca | Multiple System Atrophy | 08/25 | 08/25 | | |
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 |
|
|
| Recruiting | 2 | 640 | Europe, Canada, Japan, US, RoW | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 12/25 | 12/25 | | |
FEEMSA, NCT04706234: Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies |
|
|
| Recruiting | N/A | 200 | Europe, Japan, RoW | | Kliniken Beelitz GmbH, University Hospital Muenster, Medical University of Warsaw, University Hospital Carl Gustav Carus, University of Ulm, Medical University Innsbruck, Hannover Medical School, University of Barcelona | Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy | 12/23 | 07/24 | | |
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort |
|
|
| Recruiting | N/A | 35000 | Europe, Canada, US, RoW | | CHDI Foundation, Inc. | Huntington's Disease | 01/62 | 01/62 | | |
Wolf, Dominik |
LUSPLUS, NCT05181592: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. |
|
|
| Recruiting | 3 | 70 | Europe | Luspatercept, Reblozyl | GWT-TUD GmbH, Celgene | Myelodysplastic Syndromes | 12/24 | 06/25 | | |
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Active, not recruiting | 3 | 897 | Europe, RoW | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro | German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG) | Chronic Lymphoid Leukemia | 03/27 | 03/27 | | |
DASTOP2, NCT03573596: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment |
|
|
| Recruiting | 2 | 134 | Europe | Dasatinib | Amsterdam UMC, location VUmc, Uppsala University Hospital, Skane University Hospital, Helsinki University Central Hospital, Odense University Hospital, Henri Mondor University Hospital, St. Olavs Hospital, Helse Stavanger HF, Aarhus University Hospital, University Hospital, Bonn | CML, Relapsed | 02/23 | 02/24 | | |
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL |
|
|
| Active, not recruiting | 2 | 53 | Europe | Acalabrutinib, Calquence, ACP-196 | German CLL Study Group | Chronic Lymphoid Leukemia | 07/23 | 12/24 | | |
| Recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/27 | | |
| Recruiting | 1 | 12 | Europe | APN401 | invIOs GmbH | Advanced Solid Tumor | 03/24 | 03/24 | | |
NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry |
|
|
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Lymphocytic Leukemia | 12/27 | 12/27 | | |
| Recruiting | N/A | 130 | Europe | Next Generation Sequencing, Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction, flow cytometry, Metagenomics of stool samples, Clinical/demographic data, Elicitation of the HRQoL | Medical University Innsbruck, University Hospital, Bonn, Universitätsklinikum Leipzig | Myelodysplastic Syndromes | 01/23 | 01/23 | | |
| Recruiting | N/A | 60 | Europe | | University of Leipzig, Deutsche Krebshilfe e.V., Bonn (Germany) | MDS, MDS/MPN | 03/25 | 03/25 | | |
Löffler-Ragg, Judith |
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/24 | 12/24 | | |
| Recruiting | N/A | 120 | Europe | Pulmonary function test, Imaging, Blood sampling | Medical University Innsbruck, Boehringer Ingelheim | Connective Tissue Diseases, Interstitial Lung Disease, Systemic Sclerosis | 03/21 | 10/34 | | |
| Recruiting | N/A | 1000 | Europe | online survey | Medical University Innsbruck, Claudiana Landesfachhochschule | COVID-19 | 09/21 | 12/21 | | |
| Recruiting | N/A | 600 | Europe | | Medical University Innsbruck | Post COVID-19 Condition | 12/23 | 12/25 | | |
Virgolini, Irene |
NCT06155994: 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours |
|
|
| Completed | 1/2 | 12 | Europe | 68Ga-DOTA-MGS5, 68Ga-labelled minigastrin analogue | Medical University Innsbruck, Novartis | Neuroendocrine Tumors | 06/23 | 06/23 | | |
| Recruiting | 1/2 | 51 | Europe, US | [177Lu]-NeoB, Lutetium NeoB, [68Ga]-NeoB, Gallium NeoB, LCZ696, sacubitril/valsartan | Advanced Accelerator Applications | Neoplasms | 11/25 | 12/26 | | |
Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Active, not recruiting | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 06/24 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Recruiting | 3 | 8000 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 09/26 | 09/26 | | |
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation |
|
|
| Active, not recruiting | 2 | 100 | RoW | Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032 | Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU | Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers | 07/15 | 05/18 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
PRL-02-1001, NCT04729114: Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer |
|
|
| Recruiting | 1/2 | 100 | US | PRL-02 injection, prednisone, dexamethasone, docetaxel infusion | Astellas Pharma Global Development, Inc. | Prostate Cancer, mCRPC, mCSPC | 12/24 | 04/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Recruiting | 1 | 44 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 06/26 | 06/26 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors |
|
|
| Withdrawn | 1 | 10 | RoW | Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib | Center Trials & Treatment, BioGene Pharmaceutical | Advanced or Recurrent Solid Tumors, Breast Neoplasm | 12/23 | 01/24 | | |
|
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Recruiting | 1 | 21 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 06/26 | 08/31 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1332 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus |
|
|
| Terminated | N/A | 2432 | US, RoW | | Center Trials & Treatment, Oleg Martynenko | COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE) | 03/23 | 03/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 01/25 | 01/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 09/25 | 09/25 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Recruiting | N/A | 285 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 235 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Recruiting | N/A | 350 | US | Veye Lung nodules | Aidence | Lung; Node | 07/21 | 07/21 | | |
Helbok, Raimund |
NCT05814523: To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) |
|
|
| Withdrawn | 3 | 70 | Europe, RoW | Ganaxolone, Placebo, Standard of care | Marinus Pharmaceuticals | Refractory Status Epilepticus | 08/24 | 08/24 | | |
SENSEII/AROUSE, NCT05839418: Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE) |
|
|
| Recruiting | N/A | 3000 | Europe | | Erasme University Hospital | Status Epilepticus | 12/28 | 12/28 | | |
| Recruiting | N/A | 355 | Europe | No Intervention, Observation | Medical University Innsbruck | SARS-CoV-2, Post-acute COVID-19 Syndrome | 09/23 | 09/24 | | |
Laimer, Markus |
DiP GlucoMo, NCT05037526: Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care in Pregnancy Outcomes |
|
|
| Recruiting | N/A | 302 | Europe | Dexcom G System, Self monitoring blood glucose | University Hospital Inselspital, Berne | Gestational Diabetes | 09/23 | 03/24 | | |
Moonwalk, NCT05609175: Investigating the Relationship Between Nocturnal Glucose Levels and Motion During Sleep |
|
|
| Recruiting | N/A | 40 | Europe | | University of Bern, Insel Gruppe AG, University Hospital Bern, DCB Research AG | Diabetes, Hypoglycemia, Hyperglycemia | 08/24 | 12/24 | | |
NCT06097689: A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults With Type-1 Diabetes Mellitus |
|
|
| Completed | N/A | 21 | Europe | Lab Demo 1.0 | Spiden AG, DCB Research AG | Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus With Hypoglycemia, Type 1 Diabetes Mellitus With Hyperglycemia | 05/24 | 05/24 | | |
NCT04063098: Glucose-homeostasis After Endoscopic Sleeve Gastroplasty |
|
|
| Active, not recruiting | N/A | 15 | Europe | Oral glucose tolerance test | Insel Gruppe AG, University Hospital Bern | Obesity, Morbid | 06/24 | 07/24 | | |
| Recruiting | N/A | 1500 | Europe | | Insel Gruppe AG, University Hospital Bern, Cantonal Hospital of St. Gallen, University of Zurich | Diabetes Mellitus | 01/99 | 01/99 | | |
Raina, Amresh |
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/24 | 12/24 | | |
| Withdrawn | 2 | 30 | US | Treprostinil Diolamine | Mardi Gomberg -Maitland MD, MSc, Ohio State University, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Pulmonary Hypertension Due to Left Heart Disease | 04/25 | 04/27 | | |
| Recruiting | N/A | 3000 | US | | Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center | Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension | 10/25 | 10/25 | | |
Patel, Bela |
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/24 | 12/24 | | |
| Recruiting | 3 | 500 | US | Anticoagulant Therapy, Catheter-Directed Therapy | NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Embolism | 01/27 | 01/28 | | |
| Completed | 2/3 | 871 | US | TXA127, TRV027, Placebo, Fostamatinib | Sean Collins, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | COVID-19, SARS-CoV-2 Infection, Coronavirus Infection | 10/23 | 12/23 | | |
NCT04482595: BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients |
|
|
| Recruiting | 2 | 50 | US | BIO 300 Oral Suspension, Placebo | Humanetics Corporation, NYU Langone Health, National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19 | 06/24 | 04/25 | | |
Grimm, Michael |
| Completed | N/A | 16850 | RoW | screening, prevention and counselling, lifestyle coaching for persons with risk factors for NCDs, referral to primary healthcare facilities for further diagnosis and treatment, simple treatment of NCDs at primary healthcare level, Online monitoring and counselling for risk factors for NCDs | University Medical Center Groningen, University of Groningen, University of Passau, Universitas Sebelas Maret, Health Strategy and Policy Institute, Trnavska Universita v Trnava, HelpAge International, Thai Nguyễn University of Medicine and Pharmacy | Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases | 06/23 | 06/23 | | |
JOANNIDIS, Michael |
| Recruiting | 3 | 2400 | Europe | Cholecalciferol, Vitamin D3, Placebo | Medical University of Graz, Medical University of Vienna, Hospital Barmherzige Brüder St. Veit, Klinikum Klagenfurt am Wörthersee, Johannes Kepler University of Linz, Krankenhaus Barmherzige Schwestern Linz, Barmherzige Brüder Vienna, Erasme University Hospital, The Queen Elizabeth Hospital, Goethe University, Kages, KABEG Management, Centre Hospitalier Régional de la Citadelle, Centre Hospitalier Universitaire de Charleroi, Centre Hospitalier Universitaire Mons, Wuerzburg University Hospital, Royal Bolton Hospital NHS Foundation Trust, Heartlands Hospital, Royal Oldham Hospital, East Lancashire Hospitals NHS Trust, University of Plymouth, The Royal Victoria Hospital, Belfast, Great Western Hospital, Mid Yorkshire Teaching NHS Trust, Musgrove Park Hospital, Scunthorpe General Hospital, Guy's and St Thomas' NHS Foundation Trust, Nottingham University Hospitals, Hospital Barmherzige Brüder Graz, University Hospital Kiel, University Hospital, Bonn, Johannes Gutenberg University Mainz, University Hospital, Essen, Klinikum rechts der Isar der TUM, Landeskrankenhaus Villach | Critical Illness, Vitamin D Deficiency, Covid19 | 12/24 | 03/25 | | |
NCT04071171 / 2019-001262-15: Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation |
|
|
| Completed | 2 | 88 | Europe | CVVH with Phoxilium® in the first 48h after randomization, CVVH with Biphozyl® in the first 48h after randomization, CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®), CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®) | Medical University Innsbruck | Critically Ill, Acute Kidney Injury, Renal Replacement Therapy, Continuous Renal Replacement Therapy, Continuous Veno-Venous Hemofiltration, Replacement Fluid, Phoxilium, Biphozyl, Anticoagulation, Regional Citrate Anticoagulation | 11/23 | 03/24 | | |